tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

ABVC Stock Latest News

ABVC BioPharma’s Maitake Mushroom Dietary Supplement approved in Taiwan
The FlyABVC BioPharma’s Maitake Mushroom Dietary Supplement approved in Taiwan
7d ago
ABVC
ABVC BioPharma provides 2023 pipeline update
The FlyABVC BioPharma provides 2023 pipeline update
20d ago
ABVC
ABVC BioPharma Provides 2023 Pipeline Update
Press ReleasesABVC BioPharma Provides 2023 Pipeline Update
20d ago
ABVC
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Press ReleasesABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
25d ago
ABVC
ABVC receives Australian TGA approval to initiate Phase II study of vitargus
The FlyABVC receives Australian TGA approval to initiate Phase II study of vitargus
27d ago
ABVC
ABVC BioPharma presents ABV-1505 ADHD Phase IIa results
The FlyABVC BioPharma presents ABV-1505 ADHD Phase IIa results
2M ago
ABVC
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
Press ReleasesABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
2M ago
ABVC
ABVC announces FDA approved IND submission for study of ABV-1519
The FlyABVC announces FDA approved IND submission for study of ABV-1519
2M ago
ABVC
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
Press ReleasesFDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
2M ago
ABVC
ABVC BioPharma Provides Vitargus® Update – Phase II Vitargus® Study Protocol Received Thai FDA Approval
Press ReleasesABVC BioPharma Provides Vitargus® Update – Phase II Vitargus® Study Protocol Received Thai FDA Approval
4M ago
ABVC
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
Press ReleasesABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
4M ago
ABVC
ABVC BioPharma receives notice of allowance of patent for ABV-1504
The FlyABVC BioPharma receives notice of allowance of patent for ABV-1504
4M ago
ABVC
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
Press ReleasesABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
4M ago
ABVC
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
Press ReleasesCedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
5M ago
ABVC
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
Press ReleasesABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
6M ago
ABVC
ABVC BioPharma (NASDAQ:ABVC) in Focus on ADHD Trial Update
Market NewsABVC BioPharma (NASDAQ:ABVC) in Focus on ADHD Trial Update
6M ago
ABVC
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
Press ReleasesABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
6M ago
ABVC
ABVC Biopharma Announces Letter to Shareholders
Press ReleasesABVC Biopharma Announces Letter to Shareholders
6M ago
ABVC
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
Press ReleasesABVC BioPharma Selects Additional Vitargus® Phase II Study Site
6M ago
ABVC
ABVC Provides Oncology Pipeline Updates
Press ReleasesABVC Provides Oncology Pipeline Updates
7M ago
ABVC
ABVC BioPharma Provides Vitargus® Update
Press ReleasesABVC BioPharma Provides Vitargus® Update
7M ago
ABVC
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
Press ReleasesABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
7M ago
ABVC
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
Press ReleasesABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
8M ago
ABVC
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
Press ReleasesABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
9M ago
ABVC
ABVC BioPharma Announces Termination of Two Contracts
Press ReleasesABVC BioPharma Announces Termination of Two Contracts
9M ago
ABVC
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
Press ReleasesABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
10M ago
ABVC
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.